WHAT IS PULMONARY ARTERIAL HYPERTENSION (PAH)? Pulmonary Arterial Hypertension (PAH) is a severe and progressive form of pulmonary hypertension, characterised by elevated blood pressure in the ...

The incidence of pulmonary arterial hypertension (PAH) has increased worldwide over the past three decades, although death rates and disability-adjusted life year (DALY) rates related to the disease ...

An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple ...

Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women. Pulmonary ...

SAN ANTONIO — Patients given higher doses of oral and subcutaneous treprostinil experience a significantly longer time before their first pulmonary arterial hypertension (PAH)-related and all-cause ...

Pulmonary hypertension is characterized by increased BP in the pulmonary vasculature You will want your patients to consult a specialist to slow progression of this debilitating disease. Here's what ...

Cardiovascular disease specialists at Allegheny Health Network's (AHN) Allegheny General Hospital have become the first in the region to join a clinical trial evaluating a new medical therapy for the ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR ™ (sotatercept-csrk) compared to ...

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) prevalence is higher among Medicaid beneficiaries, with significant racial and ethnic disparities, particularly affecting Black ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) ...

“The ZENITH study represents the first PAH clinical trial with a primary endpoint comprised entirely of major outcome measures – all-cause death, lung transplantation and hospitalization for PAH,” ...